{"entity": "publication", "iuid": "ffc6bb28896f4bf3a807f710db44b029", "timestamp": "2026-08-20T20:35:38.926Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/ffc6bb28896f4bf3a807f710db44b029.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/ffc6bb28896f4bf3a807f710db44b029"}}, "title": "Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain-Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease.", "authors": [{"family": "Dulewicz", "given": "Maciej", "initials": "M", "orcid": "0000-0002-7149-017X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9ed234121de64d68a933a30e3f059099.json"}}, {"family": "Kac", "given": "Przemys\u0142aw Rados\u0142aw", "initials": "PR"}, {"family": "Ortiz", "given": "Fernando Gonzalez", "initials": "FG"}, {"family": "Karikari", "given": "Thomas K", "initials": "TK"}, {"family": "Kulczy\u0144ska-Przybik", "given": "Agnieszka", "initials": "A"}, {"family": "Mroczko", "given": "Barbara", "initials": "B"}, {"family": "Turton", "given": "Michael", "initials": "M"}, {"family": "Harrison", "given": "Peter", "initials": "P"}, {"family": "Maler", "given": "Manuel", "initials": "M"}, {"family": "Oberstein", "given": "Timo", "initials": "T"}, {"family": "Kornhuber", "given": "Johannes", "initials": "J"}, {"family": "Hanrieder", "given": "J\u00f6rg", "initials": "J"}, {"family": "Zetterberg", "given": "Henrik", "initials": "H", "orcid": "0000-0003-3930-4354", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/18365a2ea4ec4ca2baeb657cd1c8bd8f.json"}}, {"family": "Blennow", "given": "Kaj", "initials": "K"}, {"family": "Lewczuk", "given": "Piotr", "initials": "P"}], "type": "journal article", "published": "2025-12-00", "journal": {"title": "J. Neurochem.", "issn": "1471-4159", "volume": "169", "issue": "12", "pages": "e70313", "issn-l": "0022-3042"}, "abstract": "Plasma biomarkers have emerged as promising less invasive alternatives for Alzheimer's disease (AD) detection. However, the diagnostic performance of phosphorylated tau (p-tau) isoforms remains incompletely validated. In a cohort of 160 patients from a memory clinic, plasma levels of p-tau217, p-tau212, p-tau181, p-tau231, and BD-tau were measured using Single Molecule Array (Simoa) in-house assays, alongside NFL and GFAP. Subjects were classified using the Erlangen Score into Controls (n = 53), neurochemically possible AD (n = 27), and probable AD (n = 80). Plasma concentrations of all p-tau isoforms were significantly elevated in both Possible AD and Probable AD groups compared to Controls (p < 0.001). Notably, p-tau217 exhibited the highest diagnostic accuracy (AUC = 0.954) and correlated with CSF classical biomarkers. A positive result for p-tau217 increases the probability of AD almost fivefold. Plasma p-tau217 reflects AD neurochemical changes and has high negative predictive value, supporting its use as a screening tool. However, moderate PPV suggests the need for confirmatory testing to ensure an accurate diagnosis.", "doi": "10.1111/jnc.70313", "pmid": "41321279", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12666730"}], "notes": [], "created": "2026-08-20T11:18:17.380Z", "modified": "2026-08-20T11:18:17.468Z"}